LOGIN  |  REGISTER
Amneal Pharmaceuticals
Amneal Pharmaceuticals

OneMedNet Revolutionizes Data Curation with AI, Boosting Efficiency up to 5X

August 09, 2024 | Last Trade: US$0.97 0.04 4.08

MINNEAPOLIS, Aug. 09, 2024 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet” or the “Company”), the leading curator of regulatory-grade Real World Data (RWD), has successfully integrated its proprietary AI technology into its data curation process, ensuring rapid and precise de-identification of patient data. This innovation, coupled with other changes undertaken by the Company, has significantly reduced OneMedNet’s operational costs, enabling the company to process vast amounts of clinical data in minutes rather than hours. Additionally, OneMedNet can now deliver longitudinal clinical data and images to Life Science organizations up to five times faster than before, as measured from the end-to-end data curation process, significantly expediting delivery.

"The integration of AI into our de-identification processes not only enhances our data privacy but also significantly boosts our operational efficiency, allowing us to quickly provide high-quality, de-identified datasets to our customers," stated Aaron Green, CEO & President of OneMedNet. "Furthermore, AI has enabled us to respond to sales inquiries much faster, improving our customer service and overall business performance."

OneMedNet’s AI-driven de-identification process is a critical component of the company’s iRWD™ platform, which is already recognized for its ability to manage diverse clinical data, including electronic health records, laboratory results, and medical imaging. With the added layer of AI, OneMedNet is setting a new standard for how healthcare data is curated, offering unparalleled accuracy and speed in delivering regulatory-grade, de-identified datasets to its customers.

About OneMedNet Corporation

OneMedNet provides innovative solutions that unlock the significant value contained within the Real-World Data (“RWD”) repositories of over 1,400 healthcare system and provider sites that currently comprise its iRWD™ network. OneMedNet’s proprietary iRWD™ platform provides secure, comprehensive management of diverse clinical data types, including electronic health records, laboratory results, and uniquely, medical imaging. Employing its robust iRWD™ platform, the Company securely de-identifies, searches, and curates the clinical data, bringing a wealth of internal and third-party research opportunities to its drug, medical device and imaging/diagnostic AI development customers.

OneMedNet’s platform is designed to meet the clinical requirements necessary across various domains, including but not limited to rare diseases, oncology, and cardiology. The Company is committed to delivering precise and robust research support services that span the entire continuum of care. This commitment is a cornerstone of OneMedNet’s strategy to enhance patient outcomes and help pave the next wave of healthcare innovation. For more information, please visit www.onemednet.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as "may," "should," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of OneMedNet; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.

OneMedNet Contacts:

Stephen Kilmer, Investor Relations
Phone: 647.872.4849
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Michael Wong, Director of Marketing
Phone: 800.918.7189
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Stock Quote

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB